13 withdrawn. 13 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Withdrawn 13 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS) Crovalimab, Placebo, Intravenous immunoglobulin therapy - Guillain-Barré Syndrome | Phase 3 | Withdrawn | Hoffmann-La Roche | 2022-11-30 | 2022-12-15 | |
| Autologous Transplant To End NMO Spectrum Disorder Rituximab, Cyclophosphamide, Mesna - Neuromyelitis Optica, Devic's Disease | Phase 2 / Phase 3 | Withdrawn | Northwestern University | 2019-11-01 | 2019-11-20 | |
| The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis Medical Marijuana, Placebo - Multiple Sclerosis | Phase 2 / Phase 3 | Withdrawn | Colorado State University | 2017-01-01 | 2018-07-18 | |
| To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS arbaclofen ER Tablets, Placebo for arbaclofen ER tablets - Multiple Sclerosis, Sperm | Phase 3 | Withdrawn | RVL Pharmaceuticals, Inc. | 2016-07-01 | 2022-04-27 | |
| Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) dimethyl fumarate, Placebo - Relapsing-Remitting Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis | Phase 3 | Withdrawn | Biogen | 2016-05-01 | 2016-04-13 | |
| Safety and Efficacy of Fingolimod in MS Patients in China fingolimod, Placebo (6mos) + open label fingolimod (6 mos) - Multiple Sclerosis (Relapsing Remitting) | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2014-06-01 | 2017-04-21 | |
| A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Laquinimod, Avonex® - Relapsing Remitting Multiple Sclerosis | Phase 3 | Withdrawn | Teva Branded Pharmaceutical Products R&D, Inc. | 2014-01-01 | 2021-11-09 | |
| Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis BIIB017 - Relapsing Remitting Multiple Sclerosis | Phase 3 | Withdrawn | Johns Hopkins University | 2010-08-01 | 2014-09-15 | |
| Continuous Intrathecal Baclofen Infusion for Chronic Spasticity Prometra Programmable Implantable Pump System - Spasticity | Phase 3 | Withdrawn | Flowonix Medical | 2010-01-01 | 2015-03-06 | |
| Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis Simvastatin, placebo - Relapsing Remitting Multiple Sclerosis | Phase 3 | Withdrawn | Anna Tsakiri | 2008-03-01 | 2014-02-20 | |
| Improving Memory in Patients With Multiple Sclerosis donepezil, glucose - Multiple Sclerosis | Phase 3 | Withdrawn | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1999-09-01 | 2017-04-25 | |
| Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS) Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) - Multiple Sclerosis | Phase 3 | Withdrawn | Bayer | 2015-03-10 | ||
| Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis. Sativex, Placebo - Spasticity, Multiple Sclerosis | Phase 3 | Withdrawn | GW Research Ltd | 2016-08-11 |
Multiple Sclerosis (9) · Multiple Sclerosis, Relapsing-Remitting (5) · Muscle Spasticity (2) · Brain Injuries (1) · Cerebral Palsy (1) · Cognitive Dysfunction (1) · Guillain-Barre Syndrome (1) · Marijuana Abuse (1) · Multiple Sclerosis, Chronic Progressive (1) · Nervous System Diseases (1) · Neurodegenerative Diseases (1) · Neuromyelitis Optica (1) · Recurrence (1) · Stroke (1)
Autoimmune Diseases (13) · Autoimmune Diseases of the Nervous System (13) · Immune System Diseases (13) · Demyelinating Autoimmune Diseases, CNS (12) · Nervous System Diseases (12) · Pathological Conditions, Signs and Symptoms (5) · Disease Attributes (3) · Pathologic Processes (3) · Chronic Disease (2) · Mental Disorders (2) · Multiple Sclerosis (2) · Muscle Hypertonia (2) · Muscular Diseases (2) · Musculoskeletal Diseases (2)
nabiximols (2) · Antilymphocyte Serum (1) · Cannabidiol (1) · Cyclophosphamide (1) · Dimethyl Fumarate (1) · Donepezil (1) · Dronabinol (1) · Filgrastim (1) · Fingolimod Hydrochloride (1) · Glucose (1) · Granulocyte Colony-Stimulating Factor (1) · Immunoglobulin G (1) · Immunoglobulins, Intravenous (1) · Interferon beta-1a (1) · Interferon beta-1b (1)
Anna Tsakiri (1) · Bayer (1) · Biogen (1) · Colorado State University (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Flowonix Medical (1) · GW Research Ltd (1) · Hoffmann-La Roche (1) · Johns Hopkins University (1) · Northwestern University (1) · Novartis Pharmaceuticals (1) · RVL Pharmaceuticals, Inc. (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1)
United States (3) · Denmark (2) · Sweden (1)
Jette L Frederiksen, DMSC (1) · Lauren B. Krupp, MD (1) · Peter Calabresi, MD (1) · Richard Burt, MD (1) · Robert Levy, MD, PhD (1) · Sam Kaba, MD (1) · Thorsten Rudroff, PhD (1)
2014 (1)